Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Aug 15:2023.08.09.23293903.
doi: 10.1101/2023.08.09.23293903.

Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis

Affiliations

Divergent Neuroimmune Signatures in the Cerebrospinal Fluid Predict Differential Gender-Specific Survival Among Patients With HIV-Associated Cryptococcal Meningitis

Samuel Okurut et al. medRxiv. .

Update in

Abstract

Survival among people with HIV-associated cryptococcal meningitis (CM) remains low, exceptionally among women with the increased threat of death on current optimal use of antifungal drugs. Cryptococcus dissemination into the central nervous system (CNS) prompts a neuroimmune reaction to activate pathogen concomitant factors. However, no consistent diagnostic or prognostic immune-mediated signature is reported to underpin the risk of death or mechanism to improve treatment or survival. We theorized that the distinct neuroimmune cytokine or chemokine signatures in the cerebrospinal fluid (CSF), distinguish survivors from people who died on antifungal treatment, who may benefit from tailored therapy. We considered the baseline clinical disease features, cryptococcal microbiologic factors, and CSF neuroimmune modulated signatures among 419 consenting adults by gender (biological sex assigned at birth) (168 females and 251 males) by 18 weeks of survival on antifungal management. Survival at 18 weeks was inferior among females than males (47% vs. 59%; hazard ratio HR=1.4, 95% CI: 1.0 to 1.9, and p=0.023). Unsupervised principal component analysis (PCA) demonstrated the divergent neuroimmune signatures by gender, survival, and intragender-specific survival. Overall, females displayed lower levels of PD-L1, IL-1RA, and IL-15 than males (all p≤0.028). Female survivors compared with those who died, expressed significant fold elevations in levels of CSF (CCL11 - myeloid and CXCL10 - lymphoid chemokine (in both p=0.001), and CSF Th1, Th2, and Th17 cytokines. In contrast, male survivors expressed distinctly lower levels of CSF IL-15 and IL-8 compared with those who died. Survivors of either gender demonstrated a significant increase in the levels of immune regulatory element, IL-10. In the finale, we classified divergent neuroimmune key signatures in CSF by gender, survival, and intragender-specific survival among people with HIV-associated cryptococcal meningitis. These intragender-specific survival associated-neuroimmune signatures, suggests the discrete role of gender immune regulating mechanisms as the possible targets for interventions to advance therapy to improve survival among people with HIV-associated cryptococcal meningitis.

Keywords: CCL11/Eotaxin; CXCL10/IP-10; Cerebrospinal fluid; IL-5; Principal Component Analysis; cryptococcal meningitis; gender survival; neuroimmune signatures.

PubMed Disclaimer

Conflict of interest statement

7CONFLICT OF INTEREST The authors conformed to the International Committee of Medical Journal Editors (ICMJE) article publication criteria. The authors declared no conflict of interest. Study participants or funders had no role in the design, data curation, or intention to publish. Part of this work was presented in an accepted abstract and poster at the Conference on Retroviruses and Opportunistic Infections (CROI) at Seattle Convention Center, Seattle, Washington, 19–22 February 2023 and was published online on CROI website 96. SO was a doctoral fellow and the examined thesis abstract was published online by the Makerere University Online Library as a requirement degree award 97.

Figures

Figure 1.
Figure 1.
The proportion of cases with HIV-associated CM by gender and of related survival by gender in 21 published case series. These studies include 38,485 cases with 5,834 reported deaths, which accounted for a 15.2% case fatality rate (see Supplementary Table 1 for details and references ,,,,–. Bars show median values. 5 studies report survival by gender (4 references and this report; Supplemental Table 1).
Figure 2.
Figure 2.
Survival among people with HIV-associated cryptococcal meningitis. The p-value <0.05 is statistically different.
Figure 3.
Figure 3.
Projection of cytokine responses on Eigenvector correlation covariates on PC1 and PC 2 (axes) using unsupervised principal component analysis. Baseline cerebrospinal fluid (CSF) immune signature among participants who were diagnosed with HIV-associated CM showed distinct clusters by gender and by survival. PC - Principal component. Dots - show individual cytokines produced among participants projected on Eigenvector correlation covariates. Variables near the center (0; zero) are uncorrelated to the model and variables further away from the center (0; zero) are strongly correlated to the model. Variables among all cytokine projected on the variety of CSF cytokine patterns among participants by host survival (Figure 3A). The CSF secreted cytokines clustering by gender (Figure 3B). Cytokine clustering by female survival (Figure 3C). Cytokine clustering by men’s survival (Figure 3D).

References

    1. Wake RM, Govender NP, Omar T, et al. Cryptococcal-related mortality despite fluconazole preemptive treatment in a cryptococcal antigen screen-and-treat program. Clinical Infectious Diseases. 2020;70(8):1683–1690. doi: 10.1093/cid/ciz485 - DOI - PMC - PubMed
    1. Rhein J, Huppler Hullsiek K, Tugume L, et al. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial. The Lancet Infectious diseases. 2019;19(8):843–851. doi: 10.1016/S1473-3099(19)30127-6 - DOI - PMC - PubMed
    1. Hakyemez IN, Erdem H, Beraud G, et al. Prediction of unfavorable outcomes in cryptococcal meningitis: results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study. European Journal of Clinical Microbiology and Infectious Diseases. 2018;37(7):1231–1240. doi: 10.1007/s10096-017-3142-1 - DOI - PubMed
    1. Tenforde MW, Jarvis JN. HIV-associated cryptococcal meningitis: ongoing challenges and new opportunities. The Lancet Infectious Diseases. 2019;19(8):793–794. doi: 10.1016/S1473-3099(19)30295-6 - DOI - PubMed
    1. Stott KE, Loyse A, Jarvis JN, et al. Cryptococcal meningoencephalitis: time for action. The Lancet Infectious Diseases. 2021;21(9):e259–e271. doi: 10.1016/S1473-3099(20)30771-4 - DOI - PubMed

Publication types